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ABSTRACT  
Background: The EORTC QLU-C10D is a new multi-attribute utility instrument derived from the 
widely-used cancer-specific quality of life (QoL) questionnaire, EORTC QLQ-C30. It contains ten 
dimensions (Physical, Role, Social, Emotional Functioning; Pain, Fatigue, Sleep, Appetite, Nausea, 
Bowel Problems), each with 4 levels.   
Objective: To provide United Kingdom (UK) general population utility weights for the QLU-C10D. 
Methods: A UK online panel was quota-sampled to align the sample to general population 
ƉƌŽƉŽƌƚŝŽŶƐŽĨƐĞǆĂŶĚĂŐĞ ?A? ? ?ǇĞĂƌƐ ? ?dŚĞŽŶůŝŶĞǀĂůƵĂƚŝŽŶƐƵƌǀĞǇŝŶĐůƵĚĞĚ a discrete choice 
experiment (DCE) Each participant was asked to complete 16 choice-pairs, each comprising two 
QLU-C10D health states plus duration. DCE data were analysed using conditional logistic regression 
to generate utility weights. 
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Results: Data from 2,187 respondents who completed at least one choice set were included in the 
DCE analysis. The final UK QLU-C10D utility weights comprised decrements for each level of each 
health dimension. For nine of the ten dimensions (all except appetite), the expected monotonic 
pattern was observed across levels: utility decreased as severity increased. For the final model,  
consistent monotonicity was achieved by merging inconsistent adjacent levels for appetite. The 
largest utility decrements were associated with physical functioning and pain. The worst possible 
health state (the worst level of each dimension) is -0.083, which is considered slightly worse than 
being dead.  
Conclusions: UK-specific utility weights will enable cost-utility analyses (CUA) for the economic 
evaluation of new oncology therapies and technologies in the UK, where CUA is commonly used to 
inform resource allocation.  
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1. Introduction 
Economic evaluation of new health care therapies and technologies is central to decision making in 
many countries, including the United Kingdom (UK), for example through the National Institute for 
Health and Care Excellence (NICE) and the Scottish Medicines Consortium (SMC)) (1, 2). Cost-utility 
analysis (CUA) is a policy-relevant and valuable form of economic evaluation because it quantifies 
health outcomes on a metric that is applicable across health conditions. In CUA, the quality-adjusted 
life year (QALY) is a widely used metric of health which allows comparison between different disease 
areas as it captures changes in both morbidity and mortality. The quality adjustment metric used to 
calculate QALYs is a utility index (or utility weight), with a maximum of one representing full health, 
zero representing being dead, and negative values representing health states worse than death (3). 
The quality adjustment metric is usually generated using preference-based measures (PBMs) such as 
the EQ-5D (4) or SF-6D (5, 6). These have two components: a descriptive system that systematically 
describes a comprehensive set of health states (also referred to as a  ?ŚĞĂůƚŚƐƚĂƚĞĐůĂƐƐŝĨŝĐĂƚŝŽŶ
ƐǇƐƚĞŵ ? ?, and utility weights generated using a valuation survey that elicits preferences 
(conventionally from a general population sample) to yield societal preference weights. These utility 
weights produce a utility score for every health state in the classification system which can then be 
used to generate QALYs. 
PBMs can either be developed de novo or by adapting pre-existing health-related quality of life 
(HRQoL) profile measures (7, 8). The advantage of the latter approach is that it means utility weights 
can be derived using data that are already collected using an existing measure without additional 
respondent burden. Such an approach has been applied to the European Organisation for Research 
and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30), a widely-used 
questionnaire for people with cancer (9). The Multi-Attribute Utility in Cancer (MAUCa) Consortium 
is a group of international researchers who have initiated a series of country-specific value sets for 
the QLQ-C30. Previous work by Rowen et al. (10) used factor analysis and Rasch analysis on QLQ-C30 
data from a sample of 655 UK-based multiple myeloma patients to derive a descriptive system and 
then valued a subset of health states using the Time Trade-Off in face-to-face interviews conducted 
in a UK general population sample of 350. The present study uses a somewhat different descriptive 
system based on secondary analysis of a larger (n=2616) and more diverse collection of cancer-
related datasets, including 13 countries, 15 primary cancer types, localised/regional (n=1037) and 
recurrent/metastatic stages (n=1579) (11). The resultant descriptive system contains 13 of the QLQ-
 ? ? ?Ɛ ? ?ŝƚĞŵƐacross 10 dimensions (Table 1), forms the basis of the EORTC QLU-C10D, and is 
endorsed by the EORTC as its official PBM (11).  
The EORTC QLU-C10D descriptive system has been valued in an Australian general population 
sample (12, 13). However, preferences for health may differ across countries (for example see 
Ferreira et al. (14) and Norman et al. (15)). Such differences may reflect underlying cultural, social 
and work differences across countries, different sociodemographic profiles of valuation samples (for 
example see Dolan and Roberts (16)), and artefactual differences caused by use of a range of 
elicitation techniques and study protocols (17). Many international agencies specify preferred 
methods for health technology assessment submissions to inform resource allocation decisions. 
Several countries require country-specific utility weights (18). NICE in particular requires UK weights, 
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and further specifies that the utility weights should be elicited using a representative sample of the 
general population (1).  
It is important any real differences in general population preferences are reflected in utility 
algorithms, so country-specific weights need to be developed. To avoid artefactual confounding 
across countries, the MAUCa Consortium derived a standard method for valuing the EORTC QLU-
C10D in general population samples, described below. Using this method, we have estimated value 
sets in Australia (19), Europe (20) and Canada (21). The aim of this current paper is to apply this 
valuation method in a UK general population sample to produce UK-specific utility weights for the 
QLU-C10D. 
2. Methods 
2.1 The QLU-C10D 
Table 1 shows the QLU-C10D descriptive system, and explains how the 10 dimensions, each with 
four levels, map to 13 of the 30 items in the QLQ-C30. The derivation of this health state 
classification system is described elsewhere (22). It is important to note that the wording of the ten 
dimensions are based on the original wording of the QLQ-C30. For the items that use more than one 
QLQ-C30 item (specifically Physical Functioning, Social Functioning, and Bowel Function) the wording 
of the QLU-C10D levels were carefully selected to ensure translation from the original items, while 
also reflecting the inter-relatedness of the composite items. For example, the Physical Functioning 
levels assume that the problems an individual faces with a long walk are at least as bad as for a short 
walk.  
Table 1 The QLU-C10D health state classification system, how it maps to the 13 component items from 
the QLQ-C30, and the duration attribute included the discrete choice experiment (DCE) valuation survey 
Dimension Level Stem Descriptor QLQ-C30 item scores 
Physical 
Functioninga,b 
1 
zŽƵŚĂǀĞ Q 
No trouble taking a long walk outside of the house Item 2 (long walk) = 1 
2 No trouble taking a short walk outside of the 
house, but at least a little trouble taking a long 
walk 
Item 3 (short walk) = 1 AND  
Item 2  t 2  
3 At least a little trouble taking a short walk outside 
of the house, and at least a little trouble taking a 
long walk 
Item 3 = 2 AND  
Item 2 t 2  
4 Quite a bit or very much trouble taking a short 
walk outside the house  
Item 3 t 3 AND 
Item 2  t 2  
     
Role 
Functioning 
1 
You are limited in 
pursuing your work or 
ŽƚŚĞƌĚĂŝůǇĂĐƚŝǀŝƚŝĞƐ Q 
Not at all Item 6 = 1 
2 A little Item 6 = 2 
3 Quite a bit Item 6 = 3 
4 Very much Item 6 = 4 
     
Social 
Functioninga,c 
1 Your physical 
condition or medical 
treatment interferes 
with your social or 
ĨĂŵŝůǇůŝĨĞ Q 
Not at all Items 26 AND 27 = 1 
2 A little Items 26 OR 27 = 2 
3 Quite a bit Items 26 OR 27 = 3 
4 Very much Items 26 OR 27 = 4 
     
Emotional 
Functioning 
1 
zŽƵĨĞĞůĚĞƉƌĞƐƐĞĚ Q 
Not at all Item 24 = 1 
2 A little Item 24 = 2 
3 Quite a bit Item 24 = 3 
4 Very much Item 24 = 4 
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Pain 
1 
zŽƵŚĂǀĞƉĂŝŶ Q 
Not at all Item 9 = 1 
2 A little Item 9 = 2 
3 Quite a bit Item 9 = 3 
4 Very much Item 9 = 4 
     
Fatigue 
1 
zŽƵĨĞĞůƚŝƌĞĚ Q 
Not at all Item 18 = 1 
2 A little Item 18 = 2 
3 Quite a bit Item 18 = 3 
4 Very much Item 18 = 4 
     
Sleep 
1 
You have trouble 
ƐůĞĞƉŝŶŐ Q 
Not at all Item 11 = 1 
2 A little Item 11 = 2 
3 Quite a bit Item 11 = 3 
4 Very much Item 11 = 4 
     
Appetite 
1 
zŽƵůĂĐŬĂƉƉĞƚŝƚĞ Q 
Not at all Item 13 = 1 
2 A little Item 13 = 2 
3 Quite a bit Item 13 = 3 
4 Very much Item 13 = 4 
     
Nausea 
1 
You ĨĞĞůŶĂƵƐĞĂƚĞĚ Q 
Not at all Item 14 = 1 
2 A little Item 14 = 2 
3 Quite a bit Item 14 = 3 
4 Very much Item 14 = 4 
     
Bowel 
Problemsa,c  
1 
zŽƵ Q 
do not have constipation or diarrhoea at all Items 16 AND 17 = 1 
2 have a little constipation or diarrhoea Items 16 OR 17 = 2 
3 have constipation or diarrhoea quite a bit Items 16 OR 17 = 3 
4 have constipation or diarrhoea very much Items 16 OR 17 = 4 
     
Duration 
1 
You will live in this 
ŚĞĂůƚŚƐƚĂƚĞĨŽƌ Q 
1 year, and then die Not applicable 
2 2 years, and then die Not applicable 
3 5 years, and then die Not applicable 
4 10 years, and then die Not applicable 
a. Three dimensions of the QLU-C10D each involve two QLQ-C30 items.  
ď ?dŚĞWŚǇƐŝĐĂů&ƵŶĐƚŝŽŶŝŶŐĚŝŵĞŶƐŝŽŶŝŶĐůƵĚĞƐ ?ůŽŶŐǁĂůŬ ?ĂŶĚ ?ƐŚŽƌƚǁĂůŬ ?ĨƌŽŵƚŚĞY>Y-C30; for the DCE, the 
levels are determined together, but were presented in the DCE survey separately, as shown in Figure 1. 
c. For Social Functioning and Bowel Problems, the QLU-C10D level is determined by the maximum value of the 
two component items. 
 
 
2.2 The valuation task 
The study used the valuation protocol successfully developed for the Australian valuation of the 
QLU-C10D (19), with modifications only to the participant demographic section. The DCE component 
of the valuation survey was informed by previous valuation studies for the EQ-5D-3L and SF-6D 
instruments (23, 24). The DCE is a technique in which ordinal data is generated by asking 
respondents to choose between multiple alternatives typically described by a set of dimensions each 
with a range of possible levels. The inference of cardinal values from ordinal data was first proposed 
by Thurstone  (25). The random utility model, developed by McFadden (26), operationalised this 
concept. In this, utility is a function of a systematic term and a random term. When faced with a 
choice, individuals will select the option with the ŚŝŐŚĞƌƵƚŝůŝƚǇ ?DĐ&ĂĚĚĞŶ ?ƐĐŽŶĚŝƚŝŽŶĂůůŽŐŝƚ ?ĂŶĚŝƚƐ
extensions including the mixed logit and generalised multinomial logit (27), have been widely used in 
health economics generally (28), and in the field of health state valuation specifically (29). 
For the QLU-C10D, the DCE task presented pairs of QLU-C10D health states each with a specified 
duration (life years), which are described as Health States A and B (see Figure 1 for an example).  
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Figure 1: An Example Choice Set 
 
The QLU-C10D has a substantial number of dimensions, an issue that requires consideration to 
ensure respondents are able to fully consider the question being posed to them. Previous work 
explored the feasibility of the task in an online sample, and tested different presentational formats 
(13).  As illustrated in Figure 1, dimensions that differed between Health States A and B were colour 
coded in yellow.  Secondly, the Physical Functioning dimension was adapted to mitigate the impact 
of having complicated descriptors for levels 2 and 3 (see Table 1). In the DCE task, we presented 
 ?ůŽŶŐǁĂůŬ ?ĂŶĚ ?ƐŚŽƌƚǁĂůŬ ?as two separate attributes (Figure 1). However, in both the experimental 
design and data analysis, the Physical Functioning dimension was treated as a single 4-level 
dimension (online resource 1).  
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The duration levels were selected balancing a number of considerations. First, we wanted levels that 
were plausible for most respondents; offering a 90-year old 50 years would be inappropriate. 
Second, we wanted a broad enough range of years that respondents would have preferences 
between levels. Third, and in contrast with the previous point, we wanted levels that would not 
consistently dominate the choice set. The levels used here are similar to both TTO studies, and other 
DCE studies, in which duration did not dominate decisions.  
2.3 Health states valued - DCE design 
The design was the same employed in the Australian study (12), and consisted of 960 choice sets. 
Each set is a paired comparison between options consisting of two health states. Health states were 
operationalised as 12 attributes in the DCE (i.e. duration, 2 attributes for physical functioning, and 
the 9 remaining attributes). To further encourage ease of completion and comprehension, we 
simplified the cognitive task by constraining the number of HRQoL dimensions that differed between 
health states in any given choice set to four, as was the case done in the preparatory methods 
experiment (30).  
Each respondent was randomly allocated to answer 16 choice sets, but ensuring that each choice set 
was seen by a similar number of respondents. Each time a choice set was seen, which option was 
seen as Health State A or B was randomised to mitigate ordering bias. The order of dimensions was 
randomised for each person to prevent any order effect. 
2.4 Survey content 
Figure 2 presents the survey outline and ordering of sections on the survey. Beyond the DCE, the 
survey asked a range of other questions, including the general health question of the SF-36 (31).  The 
sociodemographic questions were worded to allow comparison with normative UK data (see Table 2 
for more detail). Respondents were not informed that the health states were cancer-related, as it 
has been found previously that the mention of disease labels impacts on health state values, 
probably because prior knowledge or preconceptions of health conditions distort survey 
participants ? values and preferences (32, 33). Respondents completed the QLU-C10D prior to the 
DCE tasks which familiarised respondents with the classification system. 
2.5 Survey implementation and sample recruitment 
The content was implemented by SurveyEngine (34), a company specialising in administering choice 
experiments in an online setting. SurveyEngine and its panel providers comply with the International 
Code on Market, Opinion and Social Research and Data Analytics (35). Members of the online panel 
who are residents of the UK were eligible if they were at least 18 years of age. Online panellists 
received an email invitation to participate, including a hyperlink to the survey, which they could then 
complete at their convenience. Those who chose to participate by entering the survey were 
screened based on their responses to sex and age, to ensure quotas of participants matched those of 
the UK in the most recent census (2011) (36). Recruitment continued until quota sample targets 
were achieved. Upon completion, participants received a small payment. The survey was active 
between August-October 2016. Previous work has produced well-behaved and reliable algorithms 
using 1,000 respondents (23, 24, 37); here to ensure robust estimates, a target sample size of 2,000 
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was chosen. This is considerably larger than most DCEs in health, and provides an average of 33 
observations per choice set, generally considered adequate for analysis (38).  
2.6 Statistical analysis 
2.6.1 Sample representativeness 
Sociodemographic variables were summarized using appropriate descriptive statistics, and where 
population normative data were available, Chi-squared tests or one-sampled t-tests were used to 
ĂƐƐĞƐƐŽƵƌƐĂŵƉůĞ ?ƐƉŽƉƵůĂƚŝŽŶƌĞƉƌĞƐĞŶƚĂƚŝǀĞŶĞƐƐ ?ƵƐŝŶŐSPSS Version 22 (Armonk, NY: IBM Corp). 
2.6.2 Utility estimation  
Data analysis was undertaken using STATA 13 (39) using an approach previously used to comply with 
conventional QALY framework restrictions (30, 40-42).  As described below, all terms in the utility 
function contain duration, thus we imposed the zero condition (43, 44).  A functional form that 
satisfied this requirement included the QLU-C10D dimension levels interacted with the duration 
variable  ? ?TIME ? ? (see equations 1 and 2 below). Additionally, we imposed constant proportional 
time trade off (as is standard in the QALY framework).  
The primary analysis was underpinned by Equation 1, in which the utility of option j in choice set s 
for survey respondent i was assumed to be: 
 
            (1) 
 
where D was the utility of a life year, and  was a set of dummies representing QLU-C10D health 
state levels presented in option j.  The error term  was assumed to follow a Gumbel distribution. 
The dead state is valued at zero, as TIME=0, and that removes the two parts of the systematic 
component of the utility function, as it appears in both. Thus, health states can be considered as 
worse than dead if the absolute value of D?D?௜௦௝ᇱ D?D?D?D?௜௦௝  exceeds D?D?D?D?D?௜௦௝. 
First, DCE responses were explored using a conditional logit model. Standard errors were adjusted to 
reflect intra-individual correlation through a clustered sandwich estimator (i.e. ^dd ?ƐǀĐĞ ?ĐůƵƐƚĞƌ ?
option). To estimate utility decrements for a QLU-C10D value set, we divided each of the beta terms 
by alpha (with level one omitted in each dimension to allow identification). Confidence intervals 
were then estimated around these intervals using the delta method [23].    
Model 1 included every move away from Level 1 (no problems) in each dimension within 
. Thus,  contained 30 dummies. The items in the QLU-C10D are naturally ordered. So, if 
we observed non-monotonic ordering in the coefficients for these dummies (i.e. if, as health 
worsened within each dimension, the absolute size of the coefficient increased), the non-monotonic 
adjacent levels were combined to estimate a consistent model (Model 2).  This restriction has been 
isjX c
isjH
isjX c isjX c
D?௜௦௝ ൌ D?D?D?D?D?௜௦௝ ൅ D D?௜௦௝ᇱ D?D?D?D?௜௦௝ ൅ D?௜௦௝ 
 
i  « I respondents; j = situations A, B; s  «FKRLFHVHWV 
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standardly imposed in previous studies (45-50). To estimate a value set, it was necessary to 
transform regression coefficients on to the 0-1 scale. To do this, we generated decrements for each 
level of each dimension, by dividing the relevant coefficient by the coefficient on duration (the alpha 
term in Equation 1). Then, to score individual health states, each of the decrements are subtracted 
from 1. As the decrements on the best level in each dimension are set at 0, this places the health 
state with level 1 in each dimension at 1. Goodwin and Green note that, for condition specific 
measures like the QLU-C10D, this is frequently done, but not universal (51). The reason for this 
assumption is that the QLU-C10D includes a wide variety of dimensions covering functions and 
symptoms. Thus, while it is condition-specific, we believe it is reasonable to assume that being at the 
best level in all of its dimensions reflects something close to ideal health.  
To explore robustness around the conditional logit estimates, we conducted a series of split-sample 
validations. Thus, we selected half of the data at random, estimated the conditional logit, and 
predicted the results for the other half of the data. We repeated this ten times, and estimated the 
proportion of choice sets in the hold-out correctly predicted. To further explore robustness, we re-
estimated the conditional logit adjusting for population non-representativeness in our sample. 
Specifically, we constructed inverse probability weights based on age, gender, marital status, highest 
educational attainment, and country of birth (as described in Table 2). 
In a secondary approach, we employed a mixed logit (52) which has the advantage that it models 
preference heterogeneity (53). In Model 3, we assumed that coefficients were drawn from a 
distribution,    
           (2) 
The ɲ and E terms now estimate population means, and Ji and Ki are individual-specific variations 
from them. These latter terms were assumed to follow a multivariate normal distribution  ? ? ?A吃? ?
However, the standard command limits the number of parameters drawn from a distribution to be 
no more than 20. This is problematic as we do not have a priori reasons for selecting a subset of the 
coefficients to be drawn from a distribution. Therefore, we employed pseudo-random draws, which 
allowed all coefficients to vary across individuals (personal communication, Arne Risa Hole, 
University of Sheffield, 15 June 2015). To compare models in terms of model fit, Akaike information 
criterion (AIC) and Bayesian information criterion (BIC) estimates are presented. 
3. Results 
3.1 Sample characteristics and representativeness 
Figure 2 shows the respondent flow through the survey, and Table 2 shows the sample 
sociodemographic characteristics relative to established population norms.  
  
D?௜௦௝ ൌ ൫D? ൅J௜൯D?D?D?D?௜௦௝ ൅ ሺD? ൅ D?௜ሻD?௜௦௝ᇱ D?D?D?D?௜௦௝ ൅ D?௜௦௝
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Figure 2. Flow diagram showing number of participants for each section of the survey 
 
  
 
  
Welcome and Disclosure 
Sex and Age questions  
(basis of quota sampling) 
Survey section Participants who completed each section 
71 refused, 528 did 
not respond further 
N=3372 entered 
N=2668 
409 excluded sampling 
segment quota met. 
6 did not respond. 
 
Self-reported General Health 
EORTC QLU-C10D 
classification system 
 
103 dropped out 
DCE 
2187 completed at least one choice set (included in 
DCE analysis) 
151 dropped out 
DCE feedback: layout and 
strategy questions  
2131 
0 dropped out 
Demographics 
2131 
8 dropped out 
EQ-5D-5L 
2123 
N=2290 
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Table 2. Demographic characteristics of the sample compared to UK population norms where 
availablea 
Question n 
Responders 
Level Sample 
n 
Sample 
proportion 
Population 
proportion 
p 
valueb 
Country of 
Birth 
2128 England 1694 0.796 0.719 <.001 
  
Scotland 88 0.072 0.082     
Wales 153 0.041 0.044     
Northern Ireland 45 0.021 0.029     
Republic of Ireland 2 0.001 0.007     
Other English speaking 
country 
51 0.024 0.008   
  
Other non-English speaking 
country 
95 0.045 0.111   
Highest Level 
of Education 
2086 No qualifications 109 0.052 0.232 <.001 
  
Level 1c 184 0.088 0.141     
Level 2d 319 0.153 0.152     
Apprenticeship 37 0.018 0.033     
Level 3e 351 0.168 0.121     
Level 4f 895 0.429 0.270     
Otherg 191 0.092 0.051   
Marital status 2128 Single (never married or 
never registered a same-sex 
civil partnership) 
736 0.346 0.347 <.001 
  
Married 1017 0.478 0.465     
In a registered same-sex 
civil partnership 
13 0.006 0.002   
  
Separated (but still legally 
married or still legally in a 
same-sex civil partnership) 
41 0.019 0.027   
  
Divorced or formerly in a 
same-sex civil partnership 
which is now legally 
dissolved 
221 0.104 0.088   
  
Widowed or surviving 
partner from a same-sex 
civil partnership 
100 0.047 0.070   
Sex 2303 Male 1097 0.476 0.487 0.290   
Female 1206 0.524 0.513   
Age (years) 2302 18-29 459 0.199 0.201 0.746   
30-39 374 0.162 0.165     
40-49 388 0.169 0.174     
50-59 376 0.163 0.166     
60-69 346 0.150 0.139   
    70 or older 359 0.156 0.156   
a Population values obtained from the 2011 UK census, available at 
https://www.ons.gov.uk/census#censusdataandbackground.  
b p values <0.05 suggest sample is not representative of general population. For categorical variables, the chi-squared 
goodness of fit test was used to compare observed category frequencies to those expected based on population 
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proportions; for the continuous K10 score, a one-sample t-test compared the observed K10 mean to the population value 
reported by Slade et al, 2011. 
c Level 1 is defined as 1 - 4 O levels / CSEs / GCSEs (any grades), Entry Level, Foundation Diploma, and NVQ Level 1, 
Foundation GNVQ, Basic Skills.  
d Level 2 is defined as 5+ O levels (passes) / CSEs (grade 1) / GCSEs (grades A*- C), School Certificate, 1 A level / 2 - 3 AS 
levels / VCEs, Higher Diploma and NVQ Level 2, Intermediate GNVQ, City and Guilds Craft, BTEC First / General Diploma, 
RSA Diploma.  
e Level 3 is defined as 2+ A levels / VCEs, 4+ AS levels, Higher School Certificate, Progression / Advanced Diploma and NVQ 
Level 3, Advanced GNVQ, City and Guilds Advanced Craft, ONC, OND, BTEC National, RSA Advanced Diploma.  
f Level 4+ is defined as Degree (for example BA, BSc), Higher degree (for example MA, PhD, PGCE), and Professional 
qualifications (for example teaching, nursing, accountancy), and Other vocational / work-related qualifications.  
g  ?ŽƚŚĞƌ ?ŝŶŽƵƌƐƚƵĚǇƐĂŵƉůĞŝŶĐůƵĚĞƐĂůůƉĂƌƚŝĐŝƉĂŶƚƐǁŚŽƐĞůĞĐƚĞĚƚŚĞ ?ŽƚŚĞƌ ?Žƌ ?ĨŽƌĞŝŐŶƋƵĂůŝĨŝĐĂƚŝŽŶ ?ŽƉƚŝŽŶƐ ? 
 
Participants were representative of the general population in terms of age and sex (in accordance 
with our quota sampling). However, the sample was less representative on educational attainment, 
marital status and country of birth. The study sample was more educated than the general UK 
population, and more likely to be separated or divorced. A higher proportion of participants in the 
study sample were born in England or in other English-speaking countries, compared to the general 
UK population.  
3.2 Utility estimates  
Table 3 reports the two conditional logit analyses, either with no constraints placed on coefficients 
(Model 1) or with monotonicity within each dimension imposed (Model 2). This is a fully consistent 
model where utility decreases or stays the same as health worsens for every level and dimension. 
Table 3: Conditional logit: Model 1 (unconstrained) and Model 2 (monotonicity imposeda)  
  Model 1 Model 2 
  Coefficient (Robust SE) Coefficient (Robust SE) 
Duration Linear 0.605 (0.027)*** 0.605 (0.027)*** 
Physical Functioning x 
duration 2 
-0.038 (0.010)*** 
-0.038 (0.010)*** 
 3 -0.094 (0.011)*** -0.094 (0.011)*** 
 4 -0.154 (0.010)*** -0.154 (0.010)*** 
Role Functioning  x 
duration 2 
-0.013 (0.007)* 
-0.013 (0.007)* 
 3 -0.047 (0.008)*** -0.046 (0.008)*** 
 4 -0.067 (0.007)*** -0.066 (0.007)*** 
Social Functioning  x 
duration 2 
-0.012 (0.007)* 
-0.012 (0.007)* 
 3 -0.043 (0.007)*** -0.043 (0.007)*** 
 4 -0.063 (0.007)*** -0.062 (0.007)*** 
Emotional Functioning  x 
duration 2 
-0.005 (0.007) 
-0.005 (0.007) 
 3 -0.029 (0.008)*** -0.030 (0.008)*** 
 4 -0.078 (0.007)*** -0.078 (0.007)*** 
Pain  x duration 2 -0.018 (0.007)** -0.018 (0.007)*** 
 3 -0.047 (0.008)*** -0.047 (0.007)*** 
 4 -0.091 (0.007)*** -0.091 (0.007)*** 
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a Levels combined to ensure monotonicity within each dimension are noted in italics (required only for Appetite x duration). 
As described in methods, the health problems enter as interactions with duration to impose the QALY model on the data 
Levels of statistical significance: 1% ***; 5% **; 10% * 
Respondents preferred extra years of life, as reflected in the positive and statistically significant 
coefficient on duration. For each dimension, an increased level of problems was valued negatively 
(Model 1). Of the 30 coefficients reported for levels of QLU-C10D dimensions interacted with 
duration all had the expected sign and all were significant at the 10% level, 28 were ordered 
appropriately, in that as health worsened the absolute size of the coefficient increased. In other 
words, movement to worse levels of each problem for each dimension was associated with 
increasing utility decrements (monotonicity), with the exception of the two highest levels of the 
appetite dimension. In this sample, the effect of appetite on choice was inconsistent and smaller 
than the effect of the other nine dimensions. Model 2, a fully consistent model, which combines 
levels 2, 3 and 4 of appetite (denoted in italics in the table) reports similar model fit and coefficients 
to Model 1. The coefficients for the other nine dimensions remain monotonic. As the model fit was 
not substantially impacted by constraining the model to be monotonic, and the value of 
monotonicity is apparent given the construction of the levels within each dimension, we therefore 
selected Model 2 as the preferred model for use in UK-based economic evaluations using the QLU-
C10D. 
3.3. Robustness 
Regarding the hold-out runs, the level of prediction across the ten runs ranged from 63.6% to 64.4%. 
The second robustness check, which weighted responses to adjust for population non-
representativeness on age, gender, highest educational attainment, country of birth, and marital 
status, suggested the effect of weighting was small. A scatter plot of decrements with and without 
weighting, showing the anchored coefficients in the derived value sets, is reported in Figure 3. 
Fatigue  x duration 2 -0.022 (0.006)*** -0.022 (0.006)*** 
 3 -0.029 (0.007)*** -0.029 (0.007)*** 
 4 -0.035 (0.006)*** -0.035 (0.006)*** 
Sleep  x duration 2 -0.030 (0.006)*** -0.030 (0.006)*** 
 3 -0.034 (0.007)*** -0.034 (0.007)*** 
 4 -0.043 (0.006)*** -0.043 (0.006)*** 
Appetite  x duration 2 -0.022 (0.006)*** -0.017 (0.005)*** 
 3 -0.017 (0.007)** -0.017 (0.005)*** 
 4 -0.014 (0.006)** -0.017 (0.005)*** 
Nausea  x duration 2 -0.029 (0.007)*** -0.029 (0.007)*** 
 3 -0.036 (0.007)*** -0.036 (0.007)*** 
 4 -0.057 (0.006)*** -0.057 (0.006)*** 
Bowel problems  x 
duration 2 
-0.032 (0.007)*** 
-0.032 (0.007)*** 
 3 -0.037 (0.007)*** -0.037 (0.007)*** 
 4 -0.051 (0.007)*** -0.051 (0.006)*** 
    
Log-likelihood  -18474 -18475 
Parameters  31 29 
AIC  37011 37009 
BIC  37294    37274 
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Figure 3: Scatter Plot of Weighted versus Unweighted Decrements (Model 1) 
 
 
 
 
Table 4: Mixed Logit: Model 3 
  Model 3  
  Coefficient (Robust SE) Standard Deviation (SE) 
Duration Linear 1.476 (0.040)*** 0.777 (0.022)*** 
Physical Functioning x 
duration 2 -0.126 (0.014)*** 0.101 (0.041)** 
 3 -0.155 (0.015)*** 0.157 (0.022)*** 
 4 -0.235 (0.014)*** 0.140 (0.020)*** 
Role Functioning  x 
duration 2 -0.052 (0.013)*** 0.106 (0.026)*** 
 3 -0.106 (0.014)*** 0.165 (0.018)*** 
 4 -0.120 (0.012)*** 0.108 (0.023)*** 
Social Functioning  x 
duration 2 -0.033 (0.013)** 0.131 (0.025)*** 
 3 -0.099 (0.013)*** 0.077 (0.029)*** 
 4 -0.166 (0.012)*** 0.101 (0.019)*** 
Emotional Functioning  x 
duration 2 0.022 (0.013)* 0.139 (0.017)*** 
 3 -0.060 (0.013)*** 0.056 (0.020)*** 
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In the mixed logit results (Model 3), the distribution means were generally monotonic, except in two 
dimensions. Emotional Functioning Level 2 had a positive coefficient but was not statistically 
significant (p=0.077 relative to Level 1). For Appetite, levels 3 and 4 were non-monotonic, but were 
much closer than in the conditional logit, varying by only 0.001 between levels 2, 3 and 4 (suggesting 
respondents did not (on average) discriminate between levels contingent on having any appetite 
problems.   
The value set produced using Model 2 (in Table 3) provide the weights, wdl, for calculating QLU-C10D 
scores. As is standard, a value of 1 is assigned to individuals whose are at level 1 in all 10 QLU-C10D 
dimensions. For other states, the utility score is 1 minus the aggregate utility decrement (wdl) for 
each dimension not at Level 1. Thus, the utility score for a person p, determined by their QLU-C10D 
level l for each dimension d, is: 
     
      (3) 
 
Table 5. The UK QLU-C10D Value Set 
  Model 2  
Dimension Level Utility decrement, wdl 
 4 -0.206 (0.013)*** 0.174 (0.019)*** 
Pain  x duration 2 -0.024 (0.013)* 0.137 (0.017)*** 
 3 -0.100 (0.014)*** 0.114 (0.020)*** 
 4 -0.205 (0.014)*** 0.271 (0.016)*** 
Fatigue  x duration 2 -0.027 (0.012)** 0.107 (0.021)*** 
 3 -0.045 (0.013)*** 0.055 (0.030)* 
 4 -0.083 (0.013)*** 0.175 (0.019)*** 
Sleep  x duration 2 -0.021 (0.012)* 0.127 (0.019)*** 
 3 -0.054 (0.013)*** 0.003 (0.033) 
 4 -0.079 (0.012)*** 0.119 (0.021)*** 
Appetite  x duration 2 -0.035 (0.012)*** 0.097 (0.021)*** 
 3 -0.036 (0.013)*** 0.055 (0.030)* 
 4 -0.035 (0.012)*** 0.120 (0.023)*** 
Nausea  x duration 2 -0.034 (0.012)*** 0.126 (0.020)*** 
 3 -0.073 (0.013)*** 0.122 (0.021)*** 
 4 -0.136 (0.012)*** 0.169 (0.017)*** 
Bowel problems  x 
duration 2 -0.055 (0.012)*** 0.139 (0.022)*** 
 3 -0.086 (0.013)*** 0.113 (0.021)*** 
 4 -0.134 (0.012)*** 0.160 (0.018)*** 
    
Log-likelihood  -15111  
Parameters  62  
AIC  -30098  
BIC  -29746  
Ȃ  ? ?௣  ൌ  ? ൅ ෍ D?ௗ௟ଵ଴ௗୀଵ ȁȂ  ? ?ௗ௟௣ 
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(95% CI) 
Physical Functioning (PF) 1 0 
 2 -0.062 (-0.092,-0.033) 
 3 -0.155 (-0.184,-0.125) 
 4 -0.254 (-0.281,-0.226) 
   
Role Functioning (RF) 1 0 
 2 -0.021 (-0.043,0.000) 
 3 -0.076 (-0.098,-0.054) 
 4 -0.109 (-0.130,-0.089) 
   
Social Functioning (SF) 1 0 
 2 -0.020 (-0.042,0.001) 
 3 -0.071 (-0.093,-0.049) 
 4 -0.103 (-0.123,-0.084) 
   
Emotional Functioning 
(EF) 1 
0 
 2 -0.008 (-0.031,0.014) 
 3 -0.050 (-0.073,-0.027) 
 4 -0.130 (-0.149,-0.110) 
   
Pain (Pa) 1 0 
 2 -0.030 (-0.052,-0.009) 
 3 -0.078 (-0.100,-0.056) 
 4 -0.151 (-0.170,-0.131) 
   
Fatigue (Fa) 1 0 
 2 -0.036 (-0.056,-0.016) 
 3 -0.048 (-0.069,-0.027) 
 4 -0.058 (-0.077,-0.039) 
   
Sleep (TS) 1 0 
 2 -0.049 (-0.069,-0.029) 
 3 -0.056 (-0.077,-0.036) 
 4 -0.070 (-0.090,-0.051) 
   
Appetite (Ap) 1 0 
 2 -0.029 (-0.045,-0.013) 
 3 -0.029 (-0.045,-0.013) 
 4 -0.029 (-0.045,-0.013) 
   
Nausea (Na) 1 0 
 2 -0.048 (-0.068,-0.028) 
 3 -0.059 (-0.081,-0.037) 
 4 -0.095 (-0.113,-0.076) 
   
Bowel problems (Bo) 1 0 
 2 -0.053 (-0.073,-0.033) 
 3 -0.061 (-0.083,-0.039) 
 4 -0.084 (-0.104,-0.064) 
 
Figure 4: Utility decrements from conditional logit model constrained for monotonicity (Model 2 
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algorithm) 
 
So, to give an example, health state 2221113212 (with each number relating to the level of the 
dimension as ordered in Table 4 and Figure 4) would be valued as                                                             
1-(0.062+0.021+0.02+0.056+0.029+0.053) = 0.759.  
 
4. Discussion 
This paper reports UK utility weights for the EORTC QLU-C10D, derived from the UK general 
population, which can subsequently be used to inform cost-utility analyses of interventions in 
oncology. This allows direct estimation of utility scores from responses to the QLQ-C30, a widely-
used cancer-specific HRQoL questionnaire. Thus, scores can be estimated without additional 
surveying of respondents, and can also be estimated retrospectively in studies that have not 
collected utility data. Second, relative to generic measures such as the EQ-5D or SF-6D, it is likely to 
better capture quality of life in areas most likely to be affected by cancer or cancer treatment, such 
as fatigue, nausea and bowel problems.  Arguably, this should provide a more cancer-sensitive 
measure of utility. Future research is ongoing to evaluate whether the utilities derived from the 
QLU-C10D are more sensitive to oncology treatment differences compared with utilities derived 
from the EQ-5D or other generic utility scales.    
The dimensions with the largest utility weights were the generic dimensions (particularly around role 
and pain). However, cancer-sensitive dimensions were also associated with utility decrements, 
particularly nausea and bowel problems.  Problems with sleep and fatigue had smaller decrements, 
perhaps because problems with sleep and fatigue are relatively common even in a general 
population, therefore were less influential in survey respondents ?ĐŚŽŝĐĞƐďĞƚǁĞĞŶŚĞĂůƚŚƐƚĂƚĞƐ
than other DCE attributes. The results presented here are similar in range to the Australian QLU-
PF RF SF EF Pa Fa TS Ap Na Bo
Level 2 -0.062 -0.021 -0.02 -0.008 -0.03 -0.036 -0.049 -0.029 -0.048 -0.053
Level 3 -0.155 -0.076 -0.071 -0.05 -0.078 -0.048 -0.056 -0.029 -0.059 -0.061
Level 4 -0.254 -0.109 -0.103 -0.13 -0.151 -0.058 -0.07 -0.029 -0.095 -0.084
-0.3
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-0.2
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C10D valuation results (11). In the Australian value set, the value of the worst health state was -
0.096, compared with a value of -0.083 in this UK value set.  
The unconstrained regression reported in Model 1 is largely monotonic with the exception of the 
higher levels of appetite. This effect was also seen in the Australian survey where levels 3 and 4 were 
inconsistent in the unconstrained model (12). As yet, it is uncertain why this pattern occurs. Given 
the coefficients for levels 2-4 are close to one another and small, it may be that participants 
considered appetite to be a secondary concern relative to the other attributes, and hence largely 
ignored it. Alternatively, it may be that lacking appetite is not always considered undesirable among 
many general population respondents, particularly if they are considering this from a diet and 
weight-conscious perspective rather than in the context of poor health. It may be that cancer 
patients, with appetite loss caused by disease or treatment, may have a different perception of its 
negative impact; this assertion will be tested in a cancer sample, as mentioned above. The correction 
applied in Model 2 did not substantially impact on model fit or the other utility decrements. We 
therefore believe Model 2 appropriate for use in cost-utility analyses in the UK, and recommend 
using the algorithm described in Table 5. 
The role of condition-specific preference-based measures such as the EORTC QLU-C10D is debated 
by health economists (see for example Versteegh et al and Brazier et al (7, 54)). For use in health 
technology assessments undertaken to inform resource allocation decisions, their use is often 
limited to conditions where a generic preference-based measure is not appropriate, sensitive or 
responsive, or for use in sensitivity analyses (8). This is for reasons of comparability, where health 
technology assessment is used to inform the allocation of resources across interventions, conditions 
and populations, and NICE in particular recommend EQ-5D in their reference case (1). Condition-
specific preference-based measures do have many advantages in that aspects of their content may 
seem more  relevant to patients, due to their greater focus on dimensions that are important for 
that condition, and can reduce patient burden if the data is already collected using the parent 
measure, in this case the EORTC QLQ-C30. Furthermore they enable utility values to be generated 
directly for datasets where no PBM was included; this may be desirable prospectively when patient 
burden is an issue, and retrospectively where an economic evaluation was not initially planned. For 
these reasons they can be used in sensitivity analyses for health technology assessment, and can 
provide important information that may not be captured by a generic preference-based measure. 
They also have a role outside of health technology assessment where they can be used to indicate 
both health and treatment effects (8), and for the purpose of resource allocation within the scope of 
health systems focused on cancer care (55). 
We believe the algorithm reported here is valuable for a number of reasons. It uses a standardised 
protocol allowing comparison of preferences between countries. It is likely to be sensitive to 
changes in cancer-specific quality of life, not just around the effect of the disease itself, but of the 
common side-effects associated with many common treatments. Finally, it is adapted from a widely-
used quality of life instrument, so can be applied both retrospectively and prospectively without 
requiring extra data collection and respondent burden, as noted above.  
However, it is important to note some of the possible limitations of the work. First, we have used a 
partial profile approach, in which only a subset of the dimensions differ in each choice set. However, 
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we believe that the possible loss of statistical efficiency is largely offset through higher quality of 
data and lower drop out. For example, recent work demonstrated that the use of partial profiles 
reduced the use of simplifying heuristics, and drop-out rates (56). Second, arguably online panels 
may be non-representative of the general population, not only in the sociodemographic variables 
that we recorded, but more importantly, in ways that may influence their health preferences. We do 
know that the online completion of these tasks provides similar results to face to face administration 
(57), but non-representativeness of the sample is a valid concern. However, there are similar 
concerns around non-representativeness of samples using face to face administration. 
The mixed logit results demonstrate that there is considerable heterogeneity in our sample. For 
economic evaluation that uses mean population preferences, this is arguably not a concern. 
However, an area where this might be important is in uses of the algorithm concerned with valuing a 
ƉĂƌƚŝĐƵůĂƌŝŶĚŝǀŝĚƵĂů ?ƐŚĞĂůƚŚ ?&ŽƌĐŽĞĨĨŝĐŝĞŶƚƐǁŝƚŚĂůĂƌŐĞƐƚĂŶĚĂƌĚĚĞǀŝĂƚŝŽŶ ?ƚŚĞĐĞƌƚĂŝŶƚǇǁŝƚŚ
which we can predict the value that individual places on that health state is reduced, and 
researchers working in that area should be aware of this issue. 
It is worthwhile to consider the differences between the EORTC QLU-C10D and the EORTC-8D (10) 
the existing preference-based measure from the QLQ-C30 with UK preference weights, both in terms 
of the descriptive system and the valuation algorithm. The two instruments have considerable 
overlap in dimensions and content, but the QLU-C10D contains two additional dimensions relating to 
appetite and sleep, which are not directly included in the EORTC-8D. Also, different items were 
selected to represent the dimensions of role functioning and pain. Of potentially greater importance 
is the difference in valuation approach. The EORTC-8D study used a Time Trade-Off, yielding a worst 
state value of 0.291 in comparison to -0.083 for the newer instrument. The lower value in this DCE 
may reflect the additional (and slightly amended) items, but may also reflect this difference in 
valuation technique. The impact of this difference is expected to be that, in general, the algorithm 
reported here will prioritise interventions promoting quality of life improvements, though this will 
differ depending on the exact change as the impact differs across dimensions.  Though these 
differences are of interest note that the EORTC officially endorses only the EORTC QLU-C10D. 
Further research will compare the QLU-C10D to existing generic PBMs including EQ-5D to greater 
understand the impact on QALYs from the choice of measure.   
The results presented here allow researchers to use EORTC QLQ-C30 data to populate cost-utility 
analyses. This is of considerable value given the range of cancer therapies becoming available in the 
UK and beyond, and the widespread use of the QLQ-C30.  
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Instructions for calculating EORTC QLU-C10D scores from EORTC QLQ-C30 responses 
To calculate the QLU-C10D score from QLQ-C30 responses of a particular patient p, first determine 
their QLU-C10D level l for each dimension d, following the mapping of QLQ-C30 items to QLU-C10D 
levels provided in Table 1. A utility score of 1 is assigned to patients whose QLQ-C30 scores indicate 
they are at level 1 of all 10 dimensions of the QLU-C10D. For all other health states, the utility score 
is 1 minus each the utility decrement (wdl) for each level down from no problems in each of the 10 
QLU-C10D dimensions.  
 
            
 
STATA code to calculate EORTC QLU-C10D scores from EORTC QLQ-C30 responses, based on the UK 
utility weights 
******************************************************************************** 
* Example code for converting EORTC QLQ-C30 data into QLU-C10D utility scores   
* Written by Richard Norman 
*                                         
*                  
* For further details of the QLU-C10D, see the following papers:               
*                                         
* King MT, Costa DSJ, Aaronson NK, Brazier JE, Cella DF, Fayers PM, et al. 
Derivation of the health state *classification system for the QLU-C10D, an 
internationally-valid cancer-specific multi-attribute utility instrument *derived 
from the EORTC core quality of life questionnaire, QLQ-C30. Qual Life Res. 2016. 
*King MT, Viney R, Pickard AS, Rowen D, Aaronson NK, Brazier JE, et al. Australian 
Utility Weights for the EORTC *QLU-C10D, a Multi-Attribute Utility Instrument 
Derived from the Cancer-Specific Quality of Life Questionnaire, *EORTC QLQ-C30. 
Pharmacoeconomics. 2018;36:225-38. 
*                            
*  
* The utility algorithm reported in this code is based on Model 2 results for an 
* UK general population sample, as reported above in this paper 
* 
* This code is written for STATA users, and notes are added throughout to allow 
* conversion to other software as required.                    
* 
* Any questions / comments on the instrument or code should be sent to Richard  * 
* Norman (Richard.norman@curtin.edu.au)          
*                  
******************************************************************************** 
  
******************************************************************************** 
* Stage 1: Derive of the QLU-C10D dimension levels from the corresponding EORTC  
* QLQ-C30 item responses.                    
******************************************************************************** 
 
******************************************************************************** 
* Assumption: For this code to work, it is assumed that the EORTC QLQ-C30 code  
* is set up as thirty columns, labelled qlq1-qlq30, each of which can take one  
* of four values 1-4, where 1 = "Not at all", 2 = "A little", 3 = ³Quite a      
ELW´, and 4 = ³Very much". To derive the QLU-C10D, we only need 13 of these   
* items, as described in Table 3 of King et al.(2016) and Table 1 of King et al,  
* Pharmacoeconomics DOI 10.1007/s40273-017-0582-5. 
*                                  
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* Seven of QLU-C10D items are single items from the EORTC QLQ-C30, and three    
* (PF, SF, BO) are composite, combined as described below.                       
******************************************************************************** 
 
* Generate the QLU-C10D  level for Physical Functioning from QLQ-C30 item 2  
* (long walk) and item 3 (short walk) 
 
gen pf=. 
replace pf=1 if qlq2==1 
replace pf=2 if qlq2>1  
replace pf=3 if qlq3>1 
replace pf=4 if qlq3>2 
 
*PF note: Level 1 is no problems in a long walk (and logically also in a short 
* walk). Level 2 is any problem taking a long walk but no problem taking a short * 
walk. Level 3 is a little problem with 
 a short walk (and a logically a little * or more problem with a long walk), and 
level 4 is higher level problems (quite * a bit or very much) with both short and 
long walk.      
 
* Generate the QLU-C10D level for Role Functioning from QLQ-C30 item 6 
* (work and daily activities) 
gen rf=. 
replace rf=1 if qlq6==1 
replace rf=2 if qlq6==2 
replace rf=3 if qlq6==3 
replace rf=4 if qlq6==4 
 
* Generate the QLU-C10D  level for Social Functioning from QLQ-C30 item 26  
* (family life) and item 27 (social activities)  
gen sf=. 
replace sf=1 if qlq26==1 & qlq27==1 
replace sf=2 if qlq26==2 | qlq27==2 
replace sf=3 if qlq26==3 | qlq27==3 
replace sf=4 if qlq26==4 | qlq27==4 
 
* SF note: SF in the QLU-C10D effectively uses the maximum value of either  
* qlq26 or qlq27. So if qlq26 is 4 and qlq27 is 1, the utility dimension is at  
* level 4.  The vertical bar in the code signifies OR. 
 
* Generate the QLU-C10D level for Emotional Functioning from QLQ-C30 item 24 
* (depressed) 
gen ef=. 
replace ef=1 if qlq24==1 
replace ef=2 if qlq24==2 
replace ef=3 if qlq24==3 
replace ef=4 if qlq24==4 
 
* Generate the QLU-C10D level for Pain from QLQ-C30 item 9 (pain) 
gen pa=. 
replace pa=1 if qlq9==1 
replace pa=2 if qlq9==2 
replace pa=3 if qlq9==3 
replace pa=4 if qlq9==4 
 
* Generate the QLU-C10D level for Fatigue from QLQ-C30 item 18 (tired) 
gen fa=. 
replace fa=1 if qlq18==1 
replace fa=2 if qlq18==2 
replace fa=3 if qlq18==3 
replace fa=4 if qlq18==4 
 
* Generate the QLU-C10D level for Sleep from QLQ-C30 item 11 (trouble sleeping) 
gen sl=. 
replace sl=1 if qlq11==1 
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replace sl=2 if qlq11==2 
replace sl=3 if qlq11==3 
replace sl=4 if qlq11==4 
 
* Generate the QLU-C10D level for Appetite from QLQ-C30 item 13 (lack appetite) 
gen ap=. 
replace ap=1 if qlq13==1 
replace ap=2 if qlq13==2 
replace ap=3 if qlq13==3 
replace ap=4 if qlq13==4 
 
* Generate the QLU-C10D level for Nausea from QLQ-C30 item 14 (nauseated) 
gen na=. 
replace na=1 if qlq14==1 
replace na=2 if qlq14==2 
replace na=3 if qlq14==3 
replace na=4 if qlq14==4 
 
* Generate the QLU-C10D level for Bowel Problems from QLQ-C30 item 16 (constipated) 
and item 17 (diarrhea) 
gen bo=. 
replace bo=1 if qlq16==1 & qlq17==1 
replace bo=2 if qlq16==2 | qlq17==2 
replace bo=3 if qlq16==3 | qlq17==3 
replace bo=4 if qlq16==4 | qlq17==4 
 
* BO note: BO in the QLU-C10D effectively uses the maximum value of either  
* qlq16 or qlq17. So if qlq16 is 4 and qlq17 is 1, the utility dimension is at  
* level 4. 
 
 
******************************************************************************** 
* Stage 2: Generate utility decrements and sum to estimate utility scores      *         
* The utility decrements (e.g. pfdec is the utility decrement for Physical     * 
* Functioning dimension) are derived from Table 4 of the current paper under   * 
* review, and are derived from a conditional logit constrained to be monotonic * 
* within each dimension.                                                       *                   
******************************************************************************** 
 
gen pfdec=0 
replace pfdec=-0.062 if pf==2 
replace pfdec=-0.155 if pf==3 
replace pfdec=-0.254 if pf==4 
 
gen rfdec=0 
replace rfdec=-0.021 if rf==2 
replace rfdec=-0.076 if rf==3 
replace rfdec=-0.109 if rf==4 
 
gen sfdec=0 
replace sfdec=-0.020 if sf==2 
replace sfdec=-0.071 if sf==3 
replace sfdec=-0.103 if sf==4 
 
gen efdec=0 
replace efdec=-0.008 if ef==2 
replace efdec=-0.050 if ef==3 
replace efdec=-0.130 if ef==4 
 
gen padec=0 
replace padec=-0.030 if pa==2 
replace padec=-0.078 if pa==3 
replace padec=-0.151 if pa==4 
 
gen fadec=0 
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replace fadec=-0.036 if fa==2 
replace fadec=-0.048 if fa==3 
replace fadec=-0.058 if fa==4 
 
gen sldec=0 
replace sldec=-0.049 if sl==2 
replace sldec=-0.056 if sl==3 
replace sldec=-0.070 if sl==4 
 
gen apdec=0 
replace apdec=-0.029 if ap==2 
replace apdec=-0.029 if ap==3 
replace apdec=-0.029 if ap==4 
 
gen nadec=0 
replace nadec=-0.048 if na==2 
replace nadec=-0.059 if na==3 
replace nadec=-0.095 if na==4 
 
gen bodec=0 
replace bodec=-0.053 if bo==2 
replace bodec=-0.061 if bo==3 
replace bodec=-0.084 if bo==4 
 
* Generate the QLU-C10D utility score 
gen qluc10d = 1+pfdec+rfdec+sfdec+efdec+padec+fadec+sldec+apdec+nadec+bodec 
 
replace qluc10d=. if (qlq2==. | qlq3==. | qlq6==. | qlq26==. | qlq27==. 
| qlq24==. | qlq9==. | qlq18==. | qlq11==. | qlq13==. | qlq14==. | 
qlq16==. | qlq17==.) 
 
******************************************************************************* 
* The new variable qluc10d is a utility score where full health (i.e. level 1  
* in each of the utility levels) is scored at 1, and states worse than dead are 
*scored <0. 
*These data can now be used to   
* construct quality-adjusted life years (QALYs) for cost-utility analysis.  
******************************************************************************* 
 
SPSS code to calculate EORTC QLU-C10D scores from EORTC QLQ-C30 responses, based on the 
Australian utility weights 
******************************************************************************** 
* Example code for converting EORTC QLQ-C30 data into QLU-C10D utility scores  * 
* Adapted for SPSS by Dan Costa                * 
*                                         
*   
* For further details of the QLU-C10D, see the following papers:           * 
*                                         
* King MT, Costa DSJ, Aaronson NK, Brazier JE, Cella DF, Fayers PM, et al. 
Derivation of the health state *classification system for the QLU-C10D, an 
internationally-valid cancer-specific multi-attribute utility instrument *derived 
from the EORTC core quality of life questionnaire, QLQ-C30. Qual Life Res. 2016. 
*King MT, Viney R, Pickard AS, Rowen D, Aaronson NK, Brazier JE, et al. Australian 
Utility Weights for the EORTC *QLU-C10D, a Multi-Attribute Utility Instrument 
Derived from the Cancer-Specific Quality of Life Questionnaire, *EORTC QLQ-C30. 
Pharmacoeconomics. 2018;36:225-38. 
*  
* The utility algorithm reported in this code is based on Model 2 results for an 
* UK general population sample, as reported above in this paper 
* 
* This code is written for SPSS users, and notes are added throughout to allow* 
* conversion to other software as required.                    
* 
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* Any questions / comments on the instrument or code should be sent to Daniel Costa 
daniel.costa@sydney.edu.au         * 
*  
******************************************************************************** 
 
 
 
******************************************************************************** 
* Stage 1: Derive of the QLU-C10D dimension levels from the corresponding EORTC*  
* QLQ-C30 item responses.                   * 
******************************************************************************** 
 
******************************************************************************** 
* Assumption: For this code to work, it is assumed that the EORTC QLQ-C30 code * 
* is set up as thirty columns, labelled qlq1-qlq30, each of which can take one * 
* of four values 1-4, where 1 = "Not at all", 2 = "A little", 3 = ?Quite a     * 
* bit?, and 4 = ?Very much". To derive the QLU-C10D, we only need 13 of these  * 
* items, as described in Table 3 of King et al.                    *                
* Seven of QLU_C10D items are single items from the EORTC QLQ-C30, and three   * 
* (PF, SF, BO) are composite, combined as described below.                     *  
******************************************************************************** 
 
* Generate the QLU-C10D  level for Physical Functioning from QLQ-C30 item 2  
* (long walk) and item 3 (short walk). 
compute pf=$sysmis. 
if qlq2=1 pf=1. 
if qlq2>1 pf=2. 
if qlq3>1 pf=3. 
if qlq3>2 pf=4. 
exe. 
 
 
*PF note: Level 1 is no problems in a long walk (and logically also in a short 
* walk). Level 2 is any problem taking a long walk but no problem taking a short  
* walk. Level 3 is a little problem with a short walk (and a logically a little 
* or more problem with a long walk), and level 4 is higher level problems (quite  
* a bit or very much) with both short and long walk.      
 
* Generate the QLU-C10D level for Role Functioning from QLQ-C30 item 6 
* (work and daily activities). 
compute rf=$sysmis. 
if qlq6=1 rf=1. 
if qlq6=2 rf=2. 
if qlq6=3 rf=3. 
if qlq6=4 rf=4. 
exe. 
 
 
* Generate the QLU-C10D level for Social Functioning from QLQ-C30 item 26  
* (family life) and item 27 (social activities). 
compute sf=$sysmis. 
if qlq26=1 & qlq27=1 sf=1. 
if qlq26=2 | qlq27=2 sf=2. 
if qlq26=3 | qlq27=3 sf=3. 
if qlq26=4 | qlq27=4 sf=4. 
exe. 
 
* SF note: SF in the QLU-C10D effectively uses the maximum value of either  
* qlq26 or qlq27. So if qlq26 is 4 and qlq27 is 1, the utility dimension is at  
* level 4.  The vertical bar in the code signifies OR. 
 
* Generate the QLU-C10D level for Emotional Functioning from QLQ-C30 item 24 
* (depressed). 
compute ef=$sysmis. 
if qlq24=1 ef=1. 
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if qlq24=2 ef=2. 
if qlq24=3 ef=3. 
if qlq24=4 ef=4. 
exe. 
 
* Generate the QLU-C10D level for Pain from QLQ-C30 item 9 (pain). 
compute pa=$sysmis. 
if qlq9=1 pa=1. 
if qlq9=2 pa=2. 
if qlq9=3 pa=3. 
if qlq9=4 pa=4. 
exe. 
 
* Generate the QLU-C10D level for Fatigue from QLQ-C30 item 18 (tired). 
compute fa=$sysmis. 
if qlq18=1 fa=1. 
if qlq18=2 fa=2. 
if qlq18=3 fa=3. 
if qlq18=4 fa=4. 
exe. 
 
* Generate the QLU-C10D level for Sleep from QLQ-C30 item 11 (trouble sleeping). 
compute sl=$sysmis. 
if qlq11=1 sl=1. 
if qlq11=2 sl=2. 
if qlq11=3 sl=3. 
if qlq11=4 sl=4. 
exe. 
 
* Generate the QLU-C10D level for Appetite from QLQ-C30 item 13 (lack appetite). 
compute ap=$sysmis. 
if qlq13=1 ap=1. 
if qlq13=2 ap=2. 
if qlq13=3 ap=3. 
if qlq13=4 ap=4. 
exe. 
 
* Generate the QLU-C10D level for Nausea from QLQ-C30 item 14 (nauseated). 
compute na=$sysmis. 
if qlq14=1 na=1. 
if qlq14=2 na=2. 
if qlq14=3 na=3. 
if qlq14=4 na=4. 
exe. 
 
* Generate the QLU-C10D level for Bowel Problems from QLQ-C30 item 16 (constipated) 
and item 17 (diarrhea). 
compute bo=$sysmis. 
if qlq16=1 & qlq17=1 bo=1. 
if qlq16=2 | qlq17=2 bo=2. 
if qlq16=3 | qlq17=3 bo=3. 
if qlq16=4 | qlq17=4 bo=4. 
exe. 
 
* BO note: BO in the QLU-C10D effectively uses the maximum value of either  
* qlq16 or qlq17. So if qlq16 is 4 and qlq17 is 1, the utility dimension is at  
* level 4. The vertical bar in the code signifies OR. 
 
 
******************************************************************************** 
* Stage 2: Generate utility decrements and sum to estimate utility scores      *         
* The utility decrements (e.g. pfdec is the utility decrement for Physical     * 
* Functioning dimension) are derived from Table 4 of the current paper under   * 
* review, and are derived from a conditional logit constrained to be monotonic * 
* within each dimension.                                                       *                                             
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******************************************************************************** 
 
compute pfdec=0. 
if pf=2 pfdec=-0.062. 
if pf=3 pfdec=-0.155. 
if pf=4 pfdec=-0.254. 
exe. 
 
compute rfdec=0. 
if rf=2 rfdec=-0.021. 
if rf=3 rfdec=-0.076. 
if rf=4 rfdec=-0.109. 
exe. 
 
compute sfdec=0. 
if sf=2 sfdec=-0.020. 
if sf=3 sfdec=-0.071. 
if sf=4 sfdec=-0.103. 
exe. 
 
compute efdec=0. 
if ef=2 efdec=-0.008. 
if ef=3 efdec=-0.050. 
if ef=4 efdec=-0.130. 
exe. 
 
compute padec=0. 
if pa=2 padec=-0.030. 
if pa=3 padec=-0.078. 
if pa=4 padec=-0.151. 
exe. 
 
compute fadec=0. 
if fa=2 fadec=-0.036. 
if fa=3 fadec=-0.048. 
if fa=4 fadec=-0.058. 
exe. 
 
compute sldec=0. 
if sl=2 sldec=-0.049. 
if sl=3 sldec=-0.056. 
if sl=4 sldec=-0.070. 
exe. 
 
compute apdec=0. 
if ap=2 apdec=-0.029. 
if ap=3 apdec=-0.029. 
if ap=4 apdec=-0.029. 
exe. 
 
compute nadec=0. 
if na=2 nadec=-0.048. 
if na=3 nadec=-0.059. 
if na=4 nadec=-0.095. 
exe. 
 
compute bodec=0. 
if bo=2 bodec=-0.053. 
if bo=3 bodec=-0.061. 
if bo=4 bodec=-0.084. 
exe. 
 
* Generate the QLU-C10D utility score 
compute qluc10d = 1+pfdec+rfdec+sfdec+efdec+padec+fadec+sldec+apdec+nadec+bodec. 
 
30 
 
if (sysmis(qlq2) or sysmis(qlq3) or sysmis(qlq6) or sysmis(qlq26) or sysmis(qlq27) 
or sysmis(qlq24) or sysmis(qlq9) or sysmis(qlq18) or sysmis(qlq11) or sysmis(qlq13) 
or sysmis(qlq14) or sysmis(qlq16) or sysmis(qlq17)) qluc10d=$sysmis. 
exe. 
 
* Show all decrement values to 3 decimal places. 
formats pfdec rfdec sfdec efdec padec fadec sldec apdec nadec bodec qluc10d (F6.3). 
 
******************************************************************************* 
* The new variable qluc10d is a utility score where full health (i.e. level 1  
* in each of the utility levels) is scored at 1, and states worse than dead are 
*scored <0. 
*These data can now be used to   
* construct quality-adjusted life years (QALYs) for cost-utility analysis.  
******************************************************************************* 
 
 
